Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 13/20 | 0.61 |
| ▸ | MMP2 | P08253 | 10/20 | 0.61 |
| ▸ | MMP1 | P03956 | 10/20 | 0.61 |
| ▸ | MMP9 | P14780 | 8/20 | 0.61 |
| ▸ | MMP7 | P09237 | 3/20 | 0.61 |
| ▸ | MMP14 | P50281 | 3/20 | 0.61 |
| ▸ | MMP13 | P45452 | 2/20 | 0.61 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8391834 | 0.92 | MMP3 (0.50) | MMP3MMP2MMP1MMP9MMP7 | |
| SCHEMBL7898839 | 0.88 | MMP3 (0.53) | MMP3MMP2MMP1MMP9MMP7 | |
| SCHEMBL7897166 | 0.88 | MMP3 (0.53) | MMP3MMP2MMP1MMP9MMP7 | |
| SCHEMBL8651860 | 0.86 | MMP3 (0.54) | MMP3MMP2MMP1MMP9MMP7 | |
| SCHEMBL7384875 | 0.85 | MMP1 (0.58) | MMP3MMP2MMP1MMP9MMP7 | |
| SCHEMBL7898741 | 0.85 | MMP1 (0.58) | MMP3MMP2MMP1MMP9MMP7 | |
| SCHEMBL7427129 | 0.85 | MMP1 (0.58) | MMP3MMP2MMP1MMP9MMP7 | |
| SCHEMBL6415164 | 0.85 | MMP1 (0.58) | MMP3MMP2MMP1MMP9MMP7 | |
| SCHEMBL8652723 | 0.84 | GCK (0.51) | MMP3MMP2MMP1MMP9MMP7 | |
| SCHEMBL8816353 | 0.84 | MMP3 (0.53) | MMP3MMP2MMP1MMP9MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020035065-A1 | Selective MMP inhibitors having reduced side-effects | BIRD JOHN (GB) | 2002-03-21 | — | — | US | claimed |
| EP-0784629-B1 | PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE AS INHIBITORS OF METALLOPROTEASES | DARWIN DISCOVERY LTD (GB) | 1999-04-28 | — | — | EP | claimed |
| US-6818622-B2 | ADMINISTERING OVER A PERIOD OF AT LEAST THREE MONTHS A MATRIX METALLOPROTEINASE INHIBITOR FOR TREATMENT OF A PATIENT HAVING CANCER OR INFLAMMATION | DARWIN DISCOVERY LTD. (GB) | 2004-11-16 | — | — | US | disclosed |
| EP-0981366-B1 | SELECTIVE MMP INHIBITORS HAVING REDUCED SIDE-EFFECTS | DARWIN DISCOVERY LTD (GB) | 2004-01-21 | — | — | EP | disclosed |
| US-20020035065-A1 | Selective MMP inhibitors having reduced side-effects | BIRD JOHN (GB) | 2002-03-21 | — | — | US | disclosed |
| US-6180611-B1 | INHIBITORS OF MATRIX METALLOPROTEINASES AND TUMOR NECROSIS FACTOR | DARWIN DISCOVERY, LTD. (GB) | 2001-01-30 | — | — | US | disclosed |
| EP-0784629-B1 | PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE AS INHIBITORS OF METALLOPROTEASES | DARWIN DISCOVERY LTD (GB) | 1999-04-28 | — | — | EP | disclosed |